- ISIN
- US70465T1079
- CUSIP
- 70465T107
- Sector
- Healthcare
- Industry
- Biotechnology
- IPO Date
- Oct 1, 2015
Highlights
- Market Cap
- $38.37M
- Enterprise Value
- -$11.13B
- EPS (TTM)
- -$148.74
- EBITDA (TTM)
- -$6.54B
- Year Range
- $0.51 - $1.55
- Target Price
- $9.00
- ROA (TTM)
- -29.90%
- ROE (TTM)
- -189.46%
- Avg. Volume (1M)
- 273K
- Avg. Volume Value (1M)
- $207.84K
Share Price Chart
Loading charts...
Compare stocks, funds, or ETFs
Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.
Performance
PDSB Performance Chart
PDS Biotechnology Corporation (PDSB) is down 10.9% since the beginning of the year. At $1 per share, PDSB is trading 55.7% below its 52-week high of $2. Investors who bought $1,000 worth of PDSB shares 5 years ago would now be looking at an investment worth $64.
Loading charts...
Compare this symbol against anything
Returns By Period
PDS Biotechnology Corporation (PDSB) has returned -10.87% so far this year and -37.06% over the past 12 months. Over the last ten years, PDSB has returned -42.94% per year, falling short of the S&P 500 Index benchmark, which averaged 13.26% annually.
PDS Biotechnology Corporation
- 1D
- -1.85%
- 1M
- -19.58%
- 6M
- -17.62%
- YTD
- -10.87%
- 1Y
- -37.06%
- 3Y*
- -50.60%
- 5Y*
- -42.24%
- 10Y*
- -42.94%
- ALL TIME*
- -41.59%
Benchmark (S&P 500 Index)
- 1D
- 0.70%
- 1M
- 0.09%
- 6M
- 7.94%
- YTD
- 9.41%
- 1Y
- 20.07%
- 3Y*
- 17.84%
- 5Y*
- 11.25%
- 10Y*
- 13.26%
- ALL TIME*
- 8.09%
PDSB Monthly Returns History
Based on dividend-adjusted daily data since Oct 1, 2015, PDSB's average daily return is +0.02%, while the average monthly return is +0.02%. At this rate, an investment would double in approximately 288.8 years.
Historically, 41% of months were positive and 59% were negative. The best month was May 2021 with a return of +113.3%, while the worst month was Mar 2018 at -92.2%. The longest winning streak lasted 6 consecutive months, and the longest losing streak was 6 months.
On a daily basis, PDSB closed higher 45% of trading days. The best single day was Jun 29, 2020 with a return of +60.5%, while the worst single day was Mar 28, 2018 at -91.6%.
| Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | Total | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026 | 8.18% | -18.95% | -10.37% | 60.83% | 11.00% | -18.42% | -22.13% | -10.87% | |||||
| 2025 | 0.61% | -18.90% | -10.53% | 17.65% | -1.43% | -3.62% | -19.55% | 15.89% | -18.55% | -7.42% | -17.55% | -0.16% | -52.77% |
| 2024 | 7.65% | 23.18% | -39.91% | -15.40% | -11.04% | -1.68% | 21.50% | -10.11% | 19.37% | -16.49% | -31.35% | -25.57% | -67.20% |
| 2023 | -36.89% | -8.16% | -19.61% | -1.14% | 57.57% | -47.49% | 13.62% | 2.71% | -13.97% | -17.43% | 26.14% | -5.51% | -62.35% |
| 2022 | -26.42% | 0.34% | 3.51% | -10.66% | -29.11% | -6.89% | 17.26% | -2.10% | -29.12% | 76.43% | 72.33% | 46.18% | 62.96% |
| 2021 | 42.52% | 33.11% | 12.07% | 25.71% | 113.29% | 2.87% | -14.98% | 45.74% | -4.18% | -19.19% | -18.19% | -17.77% | 278.50% |
Benchmark Metrics
PDS Biotechnology Corporation has an annualized alpha of -12.88%, beta of 1.37, and R2 of 0.06 versus S&P 500 Index. Calculated based on daily prices since October 01, 2015.
- This stock participated in 246.49% of S&P 500 Index downside but only 60.66% of its upside - more exposed to losses than it benefited from rallies.
- R2 of 0.06 means this stock moves largely independently of S&P 500 Index - capture ratios reflect limited market correlation rather than active downside protection. Consider using a more representative benchmark.
- Alpha
- -12.88%
- Beta
- 1.37
- R²
- 0.06
- Upside Capture
- 60.66%
- Downside Capture
- 246.49%
Return for Risk
Risk / Return Rank
PDSB ranks 27 for risk / return — above 27% of stocks peers on PortfoliosLab. Its historical combined result is below the peer median.
Risk / Return Metrics
The table below present risk-adjusted performance metrics for PDS Biotechnology Corporation (PDSB) and compare them to S&P 500 Index.
Values are calculated on a 1-year rolling basis and updated daily. Risk-adjusted metrics are more stable over longer periods — use the period switch above to explore them.
| PDSB | Benchmark | Difference | |
|---|---|---|---|
| Sharpe ratioReturn per unit of total volatility | -1.78 | ||
| Sortino ratioReturn per unit of downside risk | -1.93 | ||
| Omega ratioGain probability vs. loss probability | 1.01 | 1.25 | -0.25 |
| Calmar ratioReturn relative to maximum drawdown | -0.61 | 2.00 | -2.62 |
| Martin ratioReturn relative to average drawdown | -1.09 | 8.49 | -9.58 |
Dividends
Dividend History
Drawdowns
Drawdowns Chart
The Drawdowns chart displays portfolio losses from any high point along the way. Drawdowns are calculated considering price movements and all distributions paid, if any.
Loading charts...
Worst Drawdowns
The table below displays the maximum drawdowns of the PDS Biotechnology Corporation. A maximum drawdown is a measure of risk, indicating the largest reduction in portfolio value due to a series of losing trades.
The maximum drawdown for the PDS Biotechnology Corporation was 99.89%, occurring on Mar 30, 2026. The portfolio has not yet recovered.
The current PDS Biotechnology Corporation drawdown is 99.85%.
Drawdown | Fall | Recovery | Underwater | Related event |
|---|---|---|---|---|
-99.89%Mar 2026 | 10y 5mo | — | 10y 9moOct 2015 - now | — |
-5.02%Oct 2015 | 3d | 3d | 6dOct 2015 - Oct 2015 | — |
-4.02%Oct 2015 | 1d | 5d | 5dOct 2015 - Oct 2015 | — |
Drawdown Indicators
| PDSB | Benchmark | Difference | |
|---|---|---|---|
Max DrawdownLargest peak-to-trough decline | -99.89% | -56.78% | -43.11% |
Max Drawdown (1Y)Largest decline over 1 year | -58.73% | -9.10% | -49.63% |
Max Drawdown (3Y)Largest decline over 3 years | -91.86% | -18.90% | -72.96% |
Max Drawdown (5Y)Largest decline over 5 years | -96.86% | -25.43% | -71.43% |
Max Drawdown (10Y)Largest decline over 10 years | -99.85% | -33.92% | -65.93% |
Current DrawdownCurrent decline from peak | -99.85% | -1.58% | -98.27% |
Average DrawdownAverage peak-to-trough decline | -88.32% | -10.70% | -77.62% |
Ulcer IndexDepth and duration of drawdowns from previous peaks | 33.07% | 2.14% | +30.93% |
Volatility
Volatility Chart
The chart below shows the rolling one-month volatility.
Loading charts...
Financials
Financial Performance
The chart below illustrates the trends in the financial health of PDS Biotechnology Corporation over time, highlighting three key metrics: Total Revenue, Earnings Before Interest and Taxes (EBIT), and Net Income.
Valuation
The Valuation section provides an overview of how PDS Biotechnology Corporation is priced in the market compared to other companies in the Biotechnology industry. It includes key financial ratios that help investors assess whether the stock is undervalued or overvalued.
PB Ratio
The chart illustrates the Price-to-Book (P/B) ratio for PDSB in comparison with other companies in the Biotechnology industry. Currently, PDSB has a P/B value of 0.0. This P/B ratio is low compared to industry peers. It might indicate the stock is undervalued or that the company’s assets are not expected to generate strong returns.
Income Statement
| TTM | |
|---|---|
Revenue | |
Total Revenue | — |
Cost Of Revenue | — |
Gross Profit | — |
Operating Expenses | |
Selling, General & Admin Expenses | — |
R&D Expenses | — |
Depreciation And Amortization | — |
Total Operating Expenses | — |
Income | |
Income Before Tax | — |
Operating Income | — |
EBITDA | — |
EBIT | — |
Earnings From Continuing Operations | — |
Net Income | — |
Income Tax Expense | — |
Other Non-Operating Income (Expenses) | — |
Extraordinary Items | — |
Discontinued Operations | — |
Effect Of Accounting Charges | — |
Non Recurring | — |
Minority Interest | — |
Other Items | — |
Interest Income | — |
Interest Expense | — |
Net Interest Income | — |
Build a portfolio with PDSB
Add PDS Biotechnology Corporation to a portfolio and analyze allocations for your target — whether that's maximizing returns, minimizing drawdowns, or balancing risk across holdings.
Open Portfolio Analyzer with PDSB